Skip to content

G&A at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
$20.01M+22.4%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$11.23M-27.2%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$8.93M-4.7%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$33.51M+14.2%
PVL
Palvella TherapeuticsPVLA
$5.52M+45.4%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's G&A?
EyePoint, Inc. (EYPT) reported G&A of $15.24M in Q1 2026.
How has EyePoint, Inc. 's G&A changed year-over-year?
EyePoint, Inc. 's G&A increased by 9.9% year-over-year, from $13.88M to $15.24M.
What is the long-term trend for EyePoint, Inc. 's G&A?
Over 4 years (2021 to 2025), EyePoint, Inc. 's G&A has grown at a 19.2% compound annual growth rate (CAGR), from $25.58M to $51.61M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.